Bioxyne Limited (BXN) AI Stock Analysis

• Market Cap: AU$97.42M
• Dividend Yield: N/A
• Average Volume (3M): 5.68M
• Price to Earnings (P/E): 40.9
• Beta (1Y): 0.55
• Revenue Growth: 98.57%
• EPS Growth: N/A
• Country: AU
• Employees: 16
• Sector: Healthcare
• Sector Strength: 40
• Industry: Packaged Foods
• EPS (TTM): <0.01
• Shares Outstanding: 2,164,828,600
• 10 Day Avg. Volume: 4,296,774
• 30 Day Avg. Volume: 5,683,014
• PEG Ratio: 0.36
• Price to Book (P/B): 12.81
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 901.30
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 58 Neutral
• Price Target: AU$0.00 ▼(-100.00%Downside)

The overall stock score of 58 reflects strong technical momentum and price trends, offset by significant financial performance issues, such as lack of profitability and cash flow challenges. The high P/E ratio also suggests overvaluation, limiting upside potential despite positive price trends.

Bioxyne Limited Business Overview & Revenue Model

Company Description

Bioxyne Limited, a life sciences and health products company, researches, develops, markets, and distributes dietary supplement and beauty products. It perates in two segments, Wholesale Sales and Direct Sales. The company engages in developing various functional foods and beauty products. Its products portfolio includes Progastrim for Gut and Immune Health; Progastrim plus Vitamin C for cold symptoms; and proTract for atopic dermatitis (eczema) for infants. The company provides its products online, as well as through wholesale and direct sales in the United States and Asia. Bioxyne Limited was incorporated in 1998 and is headquartered in Sydney, Australia.

How the Company Makes Money

Bioxyne Limited makes money through the sale of its health and wellness products, which are distributed through various channels, including retail and direct-to-consumer platforms. The company's revenue streams are predominantly derived from its proprietary probiotic formulations and functional food products. Bioxyne has strategic partnerships and distribution agreements that help expand its reach in international markets, contributing significantly to its earnings. Additionally, the company invests in research and development to innovate and expand its product offerings, thereby driving sales growth and market presence.

Bioxyne Limited Financial Statement Overview

Summary

Bioxyne Limited shows substantial revenue growth but struggles with profitability and cash flow management. The declining asset base and consistent losses may hinder long-term financial stability. While leverage is currently manageable, the company needs to improve operational efficiency and cash generation to enhance its financial health.

Income Statement

Bioxyne Limited has shown significant revenue growth with a 80.7% increase from 2023 to 2024. However, the company struggles with profitability, as indicated by negative net profit margins and EBIT/EBITDA margins. The consistent net losses over the years highlight challenges in operational efficiency.

Balance Sheet

The balance sheet reflects moderate leverage with a manageable debt-to-equity ratio given the low total debt levels. However, the equity ratio has declined, pointing to decreased financial stability. The company's assets have decreased significantly, which could impact future growth potential.

Cash Flow

Bioxyne Limited faces challenges in cash flow management, with consistent negative free cash flow and operating cash flow. The company has not demonstrated positive free cash flow growth, indicating potential liquidity risks. The operating cash flow to net income ratio is also negative, highlighting cash generation issues.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	9.33M	5.16M	463.64K	2.11M	2.26M
Gross Profit	1.71M	343.13K	-224.10K	639.71K	638.94K
EBITDA	-1.08M	-1.88M	-463.30K	-356.42K	-440.46K
Net Income	-13.33M	-1.94M	-494.02K	-495.73K	-593.10K
Balance Sheet
Total Assets	6.70M	17.69M	445.59K	2.68M	3.34M
Cash, Cash Equivalents and Short-Term Investments	1.03M	3.85M	65.93K	1.60M	1.75M
Total Debt	673.72K	558.61K	397.39K	47.46K	47.46K
Total Liabilities	3.40M	2.69M	815.15K	744.75K	726.12K
Stockholders Equity	3.61M	15.14M	-364.84K	1.88M	2.56M
Cash Flow
Free Cash Flow	-4.05M	-897.92K	-566.88K	19.47K	14.59K
Operating Cash Flow	-3.56M	-841.28K	-506.81K	53.13K	48.25K
Investing Cash Flow	-492.66K	3.96M	26.61K	-33.66K	-33.66K
Financing Cash Flow	1.21M	947.17K	493.24K	-46.78K	-52.33K

Bioxyne Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.04
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BXN, the sentiment is Positive. The current price of 0.04 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.03, and above the 200-day MA of 0.02, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 76.34 is Negative, neither overbought nor oversold. The STOCH value of 21.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:BXN.

Bioxyne Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BXN	58 Neutral	AU$97.42M	40.91	55.63%	―	98.57%	―
Sector *	46 Neutral	C$195.87M	-3.27	-23.14%	2.82%	20.75%	-0.36%
22W0	―	€10.25M	―	-240.42%	―	―	―
CLV	64 Neutral	AU$91.01M	20.11	6.80%	2.75%	15.48%	135.65%
HCT	50 Neutral	AU$23.45M	―		―	-5.86%	98.26%
MBH	49 Neutral	AU$22.67M	―	-33.40%	―	-13.09%	-139.06%
EVE	34 Underperform	AU$7.39M	―	-105.17%	―	-3.82%	51.47%

Bioxyne Limited Corporate Events

Bioxyne Limited Announces Director’s Shareholding Adjustment

Bioxyne Limited announced a change in the director’s interest, with Mr. Anthony Ho disposing of 1,500,000 ordinary shares valued at $43,500 through an on-market sale and reallocation between accounts. This change reflects a strategic adjustment in the director’s holdings, potentially impacting investor perceptions and market dynamics for Bioxyne’s securities.

Bioxyne Limited Announces Director’s Share Disposal

Bioxyne Limited has announced a change in the interest of its director, Mr. Anthony Ho, involving the disposal of 1,500,000 ordinary shares valued at $43,500. This transaction, which involved an on-market sale and reallocation between accounts, reflects a strategic adjustment in the director’s holdings, potentially impacting investor perceptions and the company’s market dynamics.

Bioxyne Limited Releases Business Update and Progress Report

Bioxyne Limited has released a business update and progress report, highlighting its ongoing developments and strategic positioning in the pharmaceutical industry. The presentation emphasizes the company’s commitment to innovation and market expansion, although it contains forward-looking statements that are subject to change. Stakeholders are advised to consider the inherent risks and uncertainties associated with these projections.

Bioxyne Limited Expands into German Cannabis Market with €3.2 Million Agreement

Bioxyne Limited, through its subsidiary Breathe Life Sciences, has entered the German cannabis market by securing a manufacture and supply agreement worth €3.2 million (A$5.6 million) with Farmakem d.o.o. and Adrex Pharmaceuticals GmbH. This agreement involves supplying a minimum of 1,600 kg of GMP-certified medical cannabis flower, with the first delivery scheduled for September 2025. The German medical cannabis market is rapidly growing, and Bioxyne’s entry is expected to bolster its growth in FY2026, leveraging its GMP certification for competitive advantages in Germany and other European markets.

Bioxyne Limited Secures GMP Compliance to Boost Global Expansion

Bioxyne Limited, through its subsidiary Breathe Life Sciences, has received GMP compliance certificates under Mutual Recognition Agreements with several countries, including the UK, Canada, and the EU. This certification supports Bioxyne’s strategy to expand its global presence, particularly in European markets, and positions the company for growth in FY2026 as it enters new high-growth markets such as the UK and Germany.

Bioxyne Limited Prepares for Growth with Strategic Market Expansion

Bioxyne Limited is set to host a Business Update Webinar to discuss its FY2025 revenue guidance and market performance in Australia, the UK, and the EU. The company anticipates continued growth in FY2026, driven by its expansion into high-growth markets such as the UK and Germany. This strategic positioning is expected to enhance Bioxyne’s market presence and offer promising opportunities for stakeholders.

Bioxyne Limited Upgrades FY2025 Revenue Guidance Amid Strong Growth

Bioxyne Limited has upgraded its full-year FY2025 revenue guidance to $28 million, reflecting significant growth driven by its Australian pharmaceutical manufacturing and supply operations. The company reported a 267% increase in revenue for the first half of FY2025 and anticipates continued expansion in FY2026, particularly in Australia, the UK, Germany, and other EU markets. Bioxyne’s subsidiary, Breathe Life Sciences, leads the Australian market in manufacturing medicinal cannabis, MDMA, and Psilocybin products, contributing to the company’s robust performance. The company is also advancing its MDMA capsules into commercial production, positioning itself for long-term success in the growing psychedelic drugs market.

Bioxyne Limited Announces Investor Webinar for Company Update

Bioxyne Limited is hosting an online investor webinar to update shareholders and potential investors on the company’s progress and future plans. The event will feature a presentation by Managing Director Sam Watson, followed by a live Q&A session, allowing participants to engage directly with the company’s leadership.